This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Motzer RJ et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124
Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
Rini B et al. (2008) A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium: 2008 February 14–16, San Francisco, CA, USA
Bukowski RM et al. (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings Part I. J Clin Oncol 24 (Suppl 18): 4523
Melichar B et al. (2008) First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol [10.1093/annonc/mdn161]
Acknowledgements
The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Sternberg, C. Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nat Rev Urol 5, 422–423 (2008). https://doi.org/10.1038/ncpuro1157
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1157